Merus N.V


-0.02 (-0.07%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low





Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:


Company Profile

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Zeno (MCLA-128 - ntibody-dependent cell-mediated cytotoxicity (ADCC))

Neuregulin 1 Fusion Cancers (NRG1) Solid tumors

Phase 1/2

Q2 2021


Clinical program update at a major medical meeting in the second quarter of 2021.

MCLA-158 (Lgr5 x EGFR Biclonics®)

Solid Tumors

Phase 1


Data readout

Phase 1 trial continues; Update expected by year end

MCLA-145 (CD137 x PD-L1 Biclonics®)

Solid Tumors

Phase 1


Data readout

Phase 1 trial advancing as planned

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon